Middle East and Africa Cervical Cancer Diagnostic Testing Market is expected to reach US$ 282.38 million by 2028


PRESS RELEASE BY The Insight Partners 04 Mar 2022

Share this press on


Diagnostics and Research Laboratories Segment is Expected to be Fastest Growing During Forecast Period for MEA Region

According to The Insight Partners market research study on “MEA Cervical Cancer Diagnostic Testing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and Service Provider” is expected to reach US$ 282.38 million by 2028 from US$ 218.90 million in 2021. The market is estimated to grow at a CAGR of 3.7% from 2021 to 2028. The report provides trends prevailing in the MEA cervical cancer diagnostic testing market along with the drivers and restraints pertaining to the market growth.    Development opportunities in emerging countries and rising development and launch of innovative products are the major factor driving the growth of the MEA cervical cancer diagnostic testing market. However, deficiency of awareness about the diagnosis and treatment methods hinders the growth of MEA cervical cancer diagnostic testing market.      

In case of COVID-19, MEA is highly affected especially South Africa. The healthcare sector in the UAE has undergone a considerable number of infrastructure and procedural changes to position itself as a leading healthcare provider. These improvements have been more recently recognized throughout the COVID-19 pandemic due to the continuous investments made to improve the sector’s hard and soft infrastructure. However, COVID-19 is likely to continue to have a notable impact on healthcare operations in countries. The pandemic had a major impact on a wide range of health outcomes. Disordering of elective health services related to cervical screening, management of abnormal screening test results, and treatment of pre-cancers, that lead to increase in cervical cancer incidence and inflame existing health disproportions. Since, the beginning of 2020, the pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. In many countries, diagnostics services have been disrupted, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions including cervical cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on market, limited diagnosis, and decreased access to expert gynecologists further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in cervical cancer diagnosis will increase.  

The MEA cervical cancer diagnostic testing market has been segmented based on type, service provider, and country. Based on type, the market has been segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, and others. The PAP testing segment dominated the market in 2020 and HPV testing segment is expected to be fastest growing during forecast period. Based on service provider, the market has been segmented into diagnostics and research laboratories, hospitals and clinics, specialty clinics, and home care services. The diagnostics and research laboratories segment dominated the market in 2020 and same segment is expected to be fastest growing during forecast period.  Based on country, the market has been segmented into the UAE, Saudi Arabia, South Africa, and rest of MEA.

Abbott; BD; Cooper Companies, Inc.; F. Hoffmann-La Roche Ltd.; Femasys Inc.; Guided Therapeutics, Inc; Hologic, Inc.; QIAGEN; and Quest Diagnostics Incorporated are among the leading companies in the MEA cervical cancer diagnostic testing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Hologic Inc. reported the CE mark for its Genius Digital Diagnostics System in Europe. The CE mark signifies that company's product has been certified and product has met EU health, safety, and environmental requirements, which ensure consumer safety, and allows the company to sell to sell its product in European Countries.      


MEA Cervical Cancer Diagnostic Testing Market, By Country, 2020 and 2028 (%) 
MEA Cervical Cancer Diagnostic Testing Market, By Country, 2020 and 2028 (%) 


Middle East and AfricaCervical Cancer Diagnostic Testing Market to Grow at a CAGR of 3.7% to reach US$ 282.38 million from 2021 to 2028

Download Free Sample

Middle East and Africa Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care Services)     

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure